Growth trajectory STAAR Surgical has demonstrated strong recent revenue growth and profitability recovery, signaling expanding market demand for EVO ICL solutions. This presents a compelling entry point for sales teams to target ophthalmology practices, refractive surgery centers, and regional distributors with bundled offerings, training, and ongoing support to capture rising demand.

Executive leadership New appointments of a Chief Commercial Officer and a Chief Technology Officer indicate strategic shifts toward commercial expansion and product/tech innovation. Leverage these leadership changes to position advanced EVO ICL solutions, premium service contracts, and differentiated value propositions to executives at clinics and hospital networks.

Product expansion Launch of EVO+ and a focus on lens-based refractive surgery expand the product portfolio and address broader patient needs. sales opportunities exist to educate surgeons on new capabilities, expand adoption in China and other regions, and upsell to existing EVO ICL customers for upgraded hardware, training, and service plans.

Global footprint Operations in the U.S. and Switzerland with a presence in multiple countries enable regional sales strategies, localized support, and faster lead conversion. Target international ophthalmology networks and distributors, offering region-specific pricing, regulatory support, and accelerated onboarding programs to accelerate market penetration.

Financial health Strong Q2 performance with net sales around $93.5 million and profitability signals, supported by a sizable TAM in refractive surgery. Emphasize value-based pricing, favorable ROI arguments, and scalable after-sales services to drive larger case volumes, renewals, and long-term partnerships with clinics and ambulatory surgery centers.